A Phase III, Randomized, Open-Label, Parallel, Multicenter Study to Evaluate Treatment With Fixed-Dose Combination of Abacavir/Lamivudine (600mg/300mg) Once-Daily Versus Abacavir (300mg) Twice-Daily and Lamivudine (300mg) Once-Daily in Combination With Tenofovir Once-Daily and a New PI or NNRTI for 48 Weeks in ART-Experienced HIV-1 Infected Patients.

Trial Profile

A Phase III, Randomized, Open-Label, Parallel, Multicenter Study to Evaluate Treatment With Fixed-Dose Combination of Abacavir/Lamivudine (600mg/300mg) Once-Daily Versus Abacavir (300mg) Twice-Daily and Lamivudine (300mg) Once-Daily in Combination With Tenofovir Once-Daily and a New PI or NNRTI for 48 Weeks in ART-Experienced HIV-1 Infected Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Lamivudine/abacavir (Primary) ; Abacavir; Lamivudine
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 May 2009 Actual initiation date changed from Aug 2002 to Jul 2002 as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Primary endpoints identified as clinical response as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Planned number of patients changed to 166 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top